Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
Intelligent Bio Solutions (Nasdaq: INBS) has secured agreements to raise $3.8 million in gross proceeds through warrant exercises at a reduced price of $1.90 per share. The transaction involves current warrant holders exercising or prepaying existing warrants for 2,023,228 shares of common stock.
As part of the deal, participating holders will receive new Inducement Warrants for up to 4,046,456 shares at $1.90 per share, exercisable for 5.5 years after stockholder approval. The company plans to use the proceeds to complete its 510k filing with the FDA for its Fingerprint Drug Screening System and for working capital purposes. The transaction is expected to close around July 28, 2025.
Intelligent Bio Solutions (Nasdaq: INBS) ha ottenuto accordi per raccogliere 3,8 milioni di dollari di proventi lordi mediante l'esercizio di warrant a un prezzo ridotto di 1,90 dollari per azione. L'operazione coinvolge gli attuali detentori di warrant che eserciteranno o pagheranno anticipatamente i warrant esistenti per 2.023.228 azioni ordinarie.
Come parte dell'accordo, i detentori partecipanti riceveranno nuovi Warrant di Induzione per un massimo di 4.046.456 azioni a 1,90 dollari per azione, esercitabili per 5,5 anni dopo l'approvazione degli azionisti. La società prevede di utilizzare i proventi per completare la presentazione 510k alla FDA per il proprio Sistema di Screening delle Droghe Fingerprint e per scopi di capitale operativo. La chiusura dell'operazione è prevista intorno al 28 luglio 2025.
Intelligent Bio Solutions (Nasdaq: INBS) ha asegurado acuerdos para recaudar 3,8 millones de dólares en ingresos brutos mediante el ejercicio de warrants a un precio reducido de 1,90 dólares por acción. La transacción implica que los actuales tenedores de warrants ejerzan o prepaguen warrants existentes por 2.023.228 acciones ordinarias.
Como parte del acuerdo, los tenedores participantes recibirán nuevos Warrants de Inducción por hasta 4.046.456 acciones a 1,90 dólares por acción, ejercitables durante 5,5 años tras la aprobación de los accionistas. La compañía planea usar los ingresos para completar su presentación 510k ante la FDA para su Sistema de Detección de Drogas Fingerprint y para capital de trabajo. Se espera que la transacción se cierre alrededor del 28 de julio de 2025.
Intelligent Bio Solutions (나스닥: INBS)는 주당 1.90달러의 할인된 가격으로 워런트 행사 통해 총 380만 달러를 조달하는 계약을 체결했습니다. 이번 거래는 기존 워런트 보유자들이 2,023,228주의 보통주에 대해 워런트를 행사하거나 선지급하는 방식입니다.
계약의 일환으로 참여 보유자는 주주 승인 후 5.5년간 행사 가능한 4,046,456주의 신규 유인 워런트를 주당 1.90달러에 받게 됩니다. 회사는 조달 자금을 FDA에 제출할 510k 신청서 완료 및 운전자본 용도로 사용할 계획입니다. 거래는 2025년 7월 28일경 마무리될 예정입니다.
Intelligent Bio Solutions (Nasdaq : INBS) a conclu des accords pour lever 3,8 millions de dollars de produits bruts via l'exercice de bons de souscription à un prix réduit de 1,90 dollar par action. La transaction implique que les détenteurs actuels de bons exercent ou prépaiement des bons existants pour 2 023 228 actions ordinaires.
Dans le cadre de l'accord, les détenteurs participants recevront de nouveaux bons d'incitation pour jusqu'à 4 046 456 actions à 1,90 dollar par action, exerçables pendant 5,5 ans après approbation des actionnaires. La société prévoit d'utiliser les fonds pour finaliser son dossier 510k auprès de la FDA pour son système de dépistage des drogues Fingerprint et pour le fonds de roulement. La clôture de la transaction est prévue aux alentours du 28 juillet 2025.
Intelligent Bio Solutions (Nasdaq: INBS) hat Vereinbarungen getroffen, um 3,8 Millionen US-Dollar Bruttoerlös durch die Ausübung von Warrants zu einem reduzierten Preis von 1,90 US-Dollar pro Aktie zu erzielen. Die Transaktion umfasst, dass aktuelle Warranthalter bestehende Warrants für 2.023.228 Stammaktien ausüben oder vorzeitig bezahlen.
Im Rahmen der Vereinbarung erhalten teilnehmende Inhaber neue Inducement Warrants für bis zu 4.046.456 Aktien zu 1,90 US-Dollar pro Aktie, die nach Aktionärszustimmung 5,5 Jahre lang ausübbar sind. Das Unternehmen plant, die Erlöse zur Fertigstellung der 510k-Einreichung bei der FDA für sein Fingerprint Drug Screening System und für Betriebskapital zu verwenden. Der Abschluss der Transaktion wird für etwa 28. Juli 2025 erwartet.
- Secured $3.8 million in gross proceeds to fund FDA filing and operations
- Existing warrant exercise is backed by registration statements already approved by SEC
- New Inducement Warrants provide potential for additional future funding
- Warrant exercise price reduced to $1.90, representing a discount
- Additional dilution through new Inducement Warrants for over 4 million shares
- Transaction requires stockholder approval for Inducement Warrants exercise
Insights
INBS secured $3.8M funding for FDA submission of its fingerprint drug screening system through strategic warrant restructuring.
Intelligent Bio Solutions has secured
The deal's structure is particularly noteworthy as it creates immediate capital access while minimizing dilution concerns. The company has restructured its Series H-2 Warrants (originally issued March 2024) and offered new Inducement Warrants as incentives for participation. Some warrant holders opted for a prepayment approach, paying
Most critically, the funds are earmarked specifically to complete the company's 510(k) submission to the FDA for its Fingerprint Drug Screening System. This non-invasive testing technology represents INBS's core value proposition, and FDA clearance would mark a transformative milestone. The funding adequacy for completing this regulatory submission significantly de-risks one of the company's most pressing near-term challenges.
With Ladenburg Thalmann serving as placement agent, this transaction demonstrates the company's ability to access capital through existing investor relationships rather than pursuing potentially more dilutive financing options. The expected July 28 closing provides INBS with working capital continuity during this critical regulatory phase.
Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2,023,228 shares of common stock (the “Existing Warrants”) at a reduced exercise price of
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction.
The resale of the shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements that were filed and declared effective by the Securities and Exchange Commission (the “SEC”). The gross proceeds to the Company from the exercise (or prepayment of the exercise price) of the Existing Warrants are expected to be approximately
In consideration for the immediate exercise (or prepayment of the exercise price) of the Existing Warrants for cash by the current warrant holders, (i) the Company agreed to reduce the exercise price of the Series H-2 Common Stock Purchase Warrants, which warrants were issued on March 12, 2024 (the “Series H-2 Warrants”) to the reduced exercise price, and (ii) the exercising holders will receive new warrants (the “Inducement Warrants”) to purchase shares of common stock in a private placement. The Inducement Warrants will be exercisable upon the Company’s receipt of stockholder approval of the transaction into an aggregate of up to 4,046,456 shares of common stock, at an exercise price of
The transaction is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund completion of its 510k filing with the U.S. FDA for its Fingerprint Drug Screening System, for working capital and general corporate purposes.
The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Inducement Warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
How much funding did Intelligent Bio Solutions (INBS) raise in July 2025?
What will INBS use the proceeds for?
What are the terms of INBS's new Inducement Warrants?
When is the INBS warrant transaction expected to close?
Who acted as the placement agent for INBS's warrant transaction?
